Ioannis Stathopoulos died
Ioannis Stathopoulos - Owner - Energyplanning | LinkedIn
Dimitris Stathopoulos - BSS Technology Application Management & Support Manager at Coca-Cola Hellenic Bottling Company - Coca-Cola Hellenic Bottling Company | LinkedIn
JCM | Free Full-Text | Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction | HTML
Ioannis Stathopoulos - Owner - Energyplanning | LinkedIn
IJMS | Free Full-Text | The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma
7 "Yannis Stathopoulos" profiles | LinkedIn
Konstantinos Stathopoulos - Project Manager - EPIRUS SA – ΗΠΕΙΡΟΣ ΑΕΒΕ | LinkedIn
Nikolaos Stathopoulos - Postdoctoral Associate - National Center for Scientific Research "Demokritos" | LinkedIn
PDF) A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma
Nikos Stathopoulos - Greece | Professional Profile | LinkedIn
Ioannis Stathopoulos - Owner - Energyplanning | LinkedIn
30+ "Ioannis Anagnostopoulos" profiles | LinkedIn
Microorganisms | Free Full-Text | Anti–SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study
Spiros Stathopoulos - Civil Engineer - ETHNOKAT | LinkedIn
Life | Free Full-Text | Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals | HTML
CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers: Expert Opinion on Investigational Drugs: Vol 29, No 11
Obesity and Risk for Brain/CNS Tumors, Gliomas and Meningiomas: A Meta-Analysis
Cancers | Free Full-Text | A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma | HTML
Yannis Stathopoulos - Cloud Technology Strategist - Microsoft | LinkedIn
JCM | Free Full-Text | Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World “POWERFUL” Study
Ioannis Stathopoulos - Owner - Energyplanning | LinkedIn
30+ "Ioannis Anagnostopoulos" profiles | LinkedIn
Vaccines | Free Full-Text | High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events
Cancers | Free Full-Text | Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple
JCM | Free Full-Text | Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World “POWERFUL” Study
Obesity and Risk for Brain/CNS Tumors, Gliomas and Meningiomas: A Meta-Analysis
Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis: Amyloid: Vol 28, No 1
